GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Question] endpoint — what am I missing here — 67 comments in the full submission. View in context.
2.1k
c/trialwatch·submitted 3 months ago by u/yara_mensah

[Question] endpoint — what am I missing here

Discussionbranch of 8 comments

endpoint — what am I missing here. I would rather ask a basic question now than get this wrong quietly for two months. Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about. Quoted a figure here confidently, got asked whether it was ITT, went and…

Read the full submission and all 67 comments →

This branch

8 comments, started 3 months ago
u/anders_vermeulen124 points·3 months ago

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

replysharereportpermalink
u/ewan_tulloch28 points·3 months ago

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

replysharereportpermalink
u/anders_vermeulen23 points·3 months ago

Push back: an open-label extension tells you about the people who stayed. That is a different question.

replysharereportpermalink
u/ahmed_iyer14 points·3 months ago·edited

Push back: an open-label extension tells you about the people who stayed.

anders_vermeulen is right about the programme names. They are different populations with different endpoints.

replysharereportpermalink
[deleted]9 points·3 months ago

[deleted]

replysharereportpermalink
u/arne_ilunga54 points·3 months ago

Agreed. Half the arguments on this site are two people quoting different trials at each other without noticing.

replysharereportpermalink
u/alcohol_aversion30 points·3 months ago·edited

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

replysharereportpermalink
u/hub_opssite staff24 points·3 months ago

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.